Related Experiment Video
Updated: Jul 13, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer
Fukuto Maruta1, Satoshi Ishizone, Manabu Hiraguri
1Department of Surgery, Shinshu University School of Medicine, Japan. maruta@hsp.md.shinshu-u.ac.jp
Abstract:
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m2 of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment Resistant Cancers
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
